📊 TCRX Key Takeaways
Is TScan Therapeutics, Inc. (TCRX) a Good Investment?
TScan Therapeutics exhibits severe profitability challenges with losses of $29.1M against minimal $982K revenue, creating an unsustainable business model losing $30 per $1 of revenue. While the strong $128.1M cash position and excellent liquidity (6.65x current ratio) provide near-term runway, the $24.3M annual operating cash burn requires either dramatic revenue acceleration or additional capital raises that would dilute shareholders. The emerging 266.7% YoY revenue growth offers potential, but current fundamentals show a company still far from sustainable operations.
TScan Therapeutics, Inc. Key Strengths (TCRX)
- Strong cash position of $128.1M provides 5+ years of operational runway at current burn rate
- Revenue demonstrating early commercial traction with 266.7% YoY growth trajectory
- Conservative balance sheet with Debt/Equity ratio of 0.34x and $96.9M stockholders' equity
TCRX Stock Risks: TScan Therapeutics, Inc. Investment Risks
- Severe unprofitability: -$29.1M operating loss on $982K revenue indicates fundamentally unsustainable unit economics
- Ongoing cash burn of $24.3M annually with no visibility to breakeven or profitability
- High probability of future dilutive capital raises required to sustain operations as cash reserves deplete
- Pre-commercial or very early commercial stage with no proof of sustainable revenue model
Key Metrics to Watch
- Revenue growth rate trending toward profitability threshold
- Operating cash burn rate and cash depletion timeline
- Path to and timeline for achieving gross margin positive operations
- Clinical trial progress and pipeline advancement for upcoming revenue drivers
TScan Therapeutics, Inc. (TCRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.65x current ratio provides a solid financial cushion.
TCRX Profit Margin, ROE & Profitability Analysis
TCRX vs Healthcare Sector: How TScan Therapeutics, Inc. Compares
How TScan Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is TScan Therapeutics, Inc. Stock Overvalued? TCRX Valuation Analysis 2026
Based on fundamental analysis, TScan Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
TScan Therapeutics, Inc. Balance Sheet: TCRX Debt, Cash & Liquidity
TCRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: TScan Therapeutics, Inc.'s revenue has shown modest growth of 2% over the 5-year period. The most recent EPS of $-1.14 indicates the company is currently unprofitable.
TCRX Revenue Growth, EPS Growth & YoY Performance
TCRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $982.0K | -$28.7M | $-0.22 |
| Q3 2025 | $1.0M | -$29.9M | $-0.25 |
| Q2 2025 | $536.0K | -$31.7M | $-0.28 |
| Q1 2025 | $566.0K | -$30.1M | $-0.26 |
| Q3 2024 | $1.0M | -$23.0M | $-0.24 |
| Q2 2024 | $536.0K | -$24.0M | $-0.28 |
| Q1 2024 | $566.0K | -$22.6M | $-0.32 |
| Q3 2023 | $3.4M | -$16.2M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
TScan Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TCRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for TScan Therapeutics, Inc. (CIK: 0001783328)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TCRX
What is the AI rating for TCRX?
TScan Therapeutics, Inc. (TCRX) has an AI grade of C with 50% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TCRX's key strengths?
Claude: Strong cash position of $128.1M provides 5+ years of operational runway at current burn rate. Revenue demonstrating early commercial traction with 266.7% YoY growth trajectory.
What are the risks of investing in TCRX?
Claude: Severe unprofitability: -$29.1M operating loss on $982K revenue indicates fundamentally unsustainable unit economics. Ongoing cash burn of $24.3M annually with no visibility to breakeven or profitability.
What is TCRX's revenue and growth?
TScan Therapeutics, Inc. reported revenue of $982.0K.
Does TCRX pay dividends?
TScan Therapeutics, Inc. does not currently pay dividends.
Where can I find TCRX SEC filings?
Official SEC filings for TScan Therapeutics, Inc. (CIK: 0001783328) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TCRX's EPS?
TScan Therapeutics, Inc. has a diluted EPS of $-0.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TCRX's fundamental grade?
Based on our AI fundamental analysis in June 2026, TScan Therapeutics, Inc. has a C grade with 50% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TCRX stock overvalued or undervalued?
Valuation metrics for TCRX: ROE of -29.6% (sector avg: 15%), net margin of -2,919.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TCRX's AI grade for 2026?
Our dual AI analysis gives TScan Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TCRX's free cash flow?
TScan Therapeutics, Inc.'s operating cash flow is $-24.3M, with capital expenditures of $70.0K. FCF margin is -2,479.5%.
How does TCRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,919.1% (avg: 12%), ROE -29.6% (avg: 15%), current ratio 6.65 (avg: 2).